Table 1.
Baseline Characteristics by Presence of Angina in the STICH Trial
| Characteristics | Angina (n = 770) |
No angina (n = 442) |
p Value |
|---|---|---|---|
| Treatment Group | 0.52 | ||
| Medical therapy alone | 377 (49.0%) | 225 (50.9%) | |
| CABG + medical therapy | 393 (51.0%) | 217 (49.1%) | |
| Demographics | |||
| Age, median (IQR), yrs | 59 (53, 66) | 61 (54–69) | <0.001 |
| Sex, male, number (%) | 671 (87.1%) | 393 (88.9%) | 0.37 |
| BMI, median (IQR), kg/m2 | 27 (24, 30) | 27 (24–30) | 0.76 |
| Race or ethnic group, number (%) | <0.001 | ||
| White | 494 (64.2%) | 333 (75.3%) | |
| Hispanic, Latino, or nonwhite | 276 (35.8%) | 109 (24.7%) | |
| Medical history, number (%) | |||
| Previous myocardial infarction | 633 (82.2%) | 301 (68.1%) | <0.001 |
| Diabetes mellitus | 278 (36.1 %) | 200 (45.2 %) | <0.01 |
| Hypertension | 454 (59.0 %) | 274 (62.0 %) | 0.30 |
| Hyperlipidemia | 436 (56.6 %) | 294 (66.5 %) | <0.001 |
| Previous coronary artery bypass surgery | 24 (3.1 %) | 12 (2.7 %) | 0.69 |
| Previous percutaneous coronary intervention | 97 (12.6 %) | 59 (13.3 %) | 0.71 |
| Chronic renal insufficiency* | 44 (5.7 %) | 50 (11.3 %) | <0.001 |
| Previous stroke | 48 (6.2 %) | 44 (10.0 %) | 0.02 |
| Atrial flutter/fibrillation | 83 (10.8%) | 70 (15.8%) | 0.01 |
| Peripheral vascular disease | 109 (14.2%) | 75 (17.0%) | 0.19 |
| Presenting characteristics | |||
| Systolic blood pressure, median (IQR), mm Hg | 120 (110, 130) | 120 (110–130) | 0.002 |
| CSS class, number (%) | |||
| 0 | –– | 442 (100%) | |
| I | 187 (24.3%) | –– | |
| II | 525 (68.2%) | –– | |
| III | 48 (6.2%) | –– | |
| IV | 10 (1.3%) | –– | |
| NYHA class, number (%) | <0.001 | ||
| I | 261 (33.9%) | 174 (39.6%) | |
| II | 373 (48.4%) | 181 (41.2%) | |
| III | 112 (14.5%) | 69 (15.7%) | |
| IV | 24 (3.1%) | 15 (3.4%) | |
| Hemoglobin, median (IQR), g/dl | 14 (13, 15) | 14 (13–15) | 0.23 |
| Creatinine, median (IQR), mg/dl | 1.09 (0.94, 1.24) | 1.10 (0.94–1.30) | 0.04 |
| Left ventricular ejection fraction, median (IQR), % | 28 (22, 34) | 27 (22–33) | 0.06 |
| Left ventricular end-systolic volume indexed | 80 (61, 108) | 83 (62–109) | 0.44 |
| Myocardial viability† | 285 (78.1%) | 202 (85.6%) | 0.02 |
| Mitral regurgitation, number (%) | 0.11 | ||
| none/trace (1+) | 261 (33.9%) | 174 (39.6%) | |
| mild (2+) | 373 (48.4%) | 181 (41.2%) | |
| moderate (3+) | 112 (14.5%) | 69 (15.7%) | |
| severe (4+) | 24 (3.1%) | 15 (3.4%) | |
| Angiographic information | |||
| Duke CAD index, median (IQR) | 65 (39, 77) | 52 (39, 77) | 0.29 |
| Left main disease | 19 (2.5%) | 13 (2.9%) | 0.62 |
| 1-vessel disease | 76 (9.9%) | 36 (8.1%) | 0.32 |
| 2-vessel disease | 230 (29.9%) | 136 (30.8%) | 0.74 |
| 3-vessel disease | 463 (60.1%) | 270 (61.1%) | 0.74 |
| Medications, number (%) | |||
| Beta-blockers | 662 (86.0%) | 374 (84.6%) | 0.52 |
| Long-acting nitrates | 484 (62.9%) | 162 (36.7%) | <0.001 |
*
Defined as creatinine >1.5: mg/dl.
†
A total of 601 patients underwent viability assessment in the trial.
BMI = body mass index; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CCS = Canadian Cardiovascular Society; IQR = interquartile range; NYHA = New York Heart Association